Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 128

1.

Impact of a Chinese Medicinal Formula, Xiao Liu Fang, on the "3A" Ability of Endometrial Stromal Cells in Patients with Endometriosis.

Zhou H, Zhang Q, Qi C.

Mol Ther Oncolytics. 2018 Nov 13;12:1-8. doi: 10.1016/j.omto.2018.11.001. eCollection 2019 Mar 29.

2.

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.

Qin H, Ramakrishna S, Nguyen S, Fountaine TJ, Ponduri A, Stetler-Stevenson M, Yuan CM, Haso W, Shern JF, Shah NN, Fry TJ.

Mol Ther Oncolytics. 2018 Nov 6;11:127-137. doi: 10.1016/j.omto.2018.10.006. eCollection 2018 Dec 21.

3.

Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy.

Al-Shihabi A, Chawla SP, Hall FL, Gordon EM.

Mol Ther Oncolytics. 2018 Dec 12;11:122-126. doi: 10.1016/j.omto.2018.11.002. eCollection 2018 Dec 21. Review. No abstract available.

4.

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.

Havunen R, Santos JM, Sorsa S, Rantapero T, Lumen D, Siurala M, Airaksinen AJ, Cervera-Carrascon V, Tähtinen S, Kanerva A, Hemminki A.

Mol Ther Oncolytics. 2018 Nov 6;11:109-121. doi: 10.1016/j.omto.2018.10.005. eCollection 2018 Dec 21.

5.

Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis.

Sakurai Y, Hada T, Kato A, Hagino Y, Mizumura W, Harashima H.

Mol Ther Oncolytics. 2018 Oct 30;11:102-108. doi: 10.1016/j.omto.2018.10.004. eCollection 2018 Dec 21.

6.

Recombinant Adenovirus KGHV500 and CIK Cells Codeliver Anti-p21-Ras scFv for the Treatment of Gastric Cancer with Wild-Type Ras Overexpression.

Wang M, Hong Y, Feng Q, Pan X, Song S, Cui J, Lei J, Fang H, Yang J.

Mol Ther Oncolytics. 2018 Oct 23;11:90-101. doi: 10.1016/j.omto.2018.10.003. eCollection 2018 Dec 21.

7.

Functional Gene Knockout of NRF2 Increases Chemosensitivity of Human Lung Cancer A549 Cells In Vitro and in a Xenograft Mouse Model.

Bialk P, Wang Y, Banas K, Kmiec EB.

Mol Ther Oncolytics. 2018 Oct 18;11:75-89. doi: 10.1016/j.omto.2018.10.002. eCollection 2018 Dec 21.

8.

Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.

Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang PY, Srinivas R, Cassady KA, Goins WF, Cripe TP.

Mol Ther Oncolytics. 2018 Oct 18;11:62-74. doi: 10.1016/j.omto.2018.10.001. eCollection 2018 Dec 21.

9.

Glioblastoma Bystander Cell Therapy: Improvements in Treatment and Insights into the Therapy Mechanisms.

Guerra-Rebollo M, Nogueira de Moraes C, Alcoholado C, Soler-Botija C, Sanchez-Cid L, Vila OF, Meca-Cortés O, Ramos-Romero S, Rubio N, Becerra J, Blanco J, Garrido C.

Mol Ther Oncolytics. 2018 Sep 15;11:39-51. doi: 10.1016/j.omto.2018.09.002. eCollection 2018 Dec 21.

10.

Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma.

Phelps MP, Yang H, Patel S, Rahman MM, McFadden G, Chen E.

Mol Ther Oncolytics. 2018 Sep 15;11:52-61. doi: 10.1016/j.omto.2018.09.001. eCollection 2018 Dec 21.

11.

Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas.

Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, Cook DR, Thokala R, Blouch K, McGettigan-Croce B, Zhang L, Konradt C, Cogdill AP, Panjwani MK, Jiang S, Migliorini D, Dahmane N, Posey AD Jr, June CH, Mason NJ, Lin Z, O'Rourke DM, Johnson LA.

Mol Ther Oncolytics. 2018 Aug 28;11:20-38. doi: 10.1016/j.omto.2018.08.002. eCollection 2018 Dec 21.

12.

miR-93 Promotes the Growth and Invasion of Prostate Cancer by Upregulating Its Target Genes TGFBR2, ITGB8, and LATS2.

Liu JJ, Zhang X, Wu XH.

Mol Ther Oncolytics. 2018 Aug 16;11:14-19. doi: 10.1016/j.omto.2018.08.001. eCollection 2018 Dec 21.

13.

APOBEC3 Mediates Resistance to Oncolytic Viral Therapy.

Huff AL, Wongthida P, Kottke T, Thompson JM, Driscoll CB, Schuelke M, Shim KG, Harris RS, Molan A, Pulido JS, Selby PJ, Harrington KJ, Melcher A, Evgin L, Vile RG.

Mol Ther Oncolytics. 2018 Aug 29;11:1-13. doi: 10.1016/j.omto.2018.08.003. eCollection 2018 Dec 21.

14.

Overexpression of microRNA-34a Attenuates Proliferation and Induces Apoptosis in Pituitary Adenoma Cells via SOX7.

Yang Z, Zhang T, Wang Q, Gao H.

Mol Ther Oncolytics. 2018 Jul 9;10:40-47. doi: 10.1016/j.omto.2018.07.001. eCollection 2018 Sep 28.

15.

Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression.

Beug ST, Pichette SJ, St-Jean M, Holbrook J, Walker DE, LaCasse EC, Korneluk RG.

Mol Ther Oncolytics. 2018 Jun 21;10:28-39. doi: 10.1016/j.omto.2018.06.002. eCollection 2018 Sep 28.

16.

Visualizing Oncolytic Virus-Host Interactions in Live Mice Using Intravital Microscopy.

Naumenko V, Van S, Dastidar H, Kim DS, Kim SJ, Zeng Z, Deniset J, Lau A, Zhang C, Macia N, Heyne B, Jenne CN, Mahoney DJ.

Mol Ther Oncolytics. 2018 Jul 14;10:14-27. doi: 10.1016/j.omto.2018.06.001. eCollection 2018 Sep 28.

17.

Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers.

Suksanpaisan L, Xu R, Tesfay MZ, Bomidi C, Hamm S, Vandergaast R, Jenks N, Steele MB, Ota-Setlik A, Akhtar H, Luckay A, Nowak R, Peng KW, Eldridge JH, Clarke DK, Russell SJ, Diaz RM.

Mol Ther Oncolytics. 2018 Jul 5;10:1-13. doi: 10.1016/j.omto.2018.05.001. eCollection 2018 Sep 28.

18.

Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.

Hemminki O, Oksanen M, Taipale K, Liikanen I, Koski A, Joensuu T, Kanerva A, Hemminki A.

Mol Ther Oncolytics. 2018 Apr 22;9:41-50. doi: 10.1016/j.omto.2018.04.003. eCollection 2018 Jun 29.

19.

Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.

Annels NE, Arif M, Simpson GR, Denyer M, Moller-Levet C, Mansfield D, Butler R, Shafren D, Au G, Knowles M, Harrington K, Vile R, Melcher A, Pandha H.

Mol Ther Oncolytics. 2018 Feb 14;9:1-12. doi: 10.1016/j.omto.2018.02.001. eCollection 2018 Jun 29.

20.

Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity.

Scherwitzl I, Hurtado A, Pierce CM, Vogt S, Pampeno C, Meruelo D.

Mol Ther Oncolytics. 2018 May 3;9:51-63. doi: 10.1016/j.omto.2018.04.004. eCollection 2018 Jun 29.

Supplemental Content

Loading ...
Support Center